S. Sundaram

发表

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

M. Davids, J. Pagel, K. Rogers, 2021, Blood.

Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

P. Wallace, F. Hernandez-Ilizaliturri, S. Sait, 2022, Cancer.

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.

Scott E. Smith, I. Lossos, S. Montoto, 2021, Blood advances.

FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials.

M. de Lima, E. Malek, J. Driscoll, 2018, American journal of nuclear medicine and molecular imaging.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 4.2020

J. Byrd, T. Kipps, M. Dwyer, 2020 .

Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain-Barré syndrome: A diagnostic and therapeutic challenge.

Brototo Deb, P. Torka, S. Sundaram, 2020, Hematology/oncology and stem cell therapy.

Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era – tissue remains the issue

F. Hernandez-Ilizaliturri, K. Attwood, P. Torka, 2020, Leukemia & lymphoma.

Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature.

C. Magro, U. Gergis, S. Sundaram, 2014, Hematology/oncology and stem cell therapy.

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

F. Hernandez-Ilizaliturri, L. Suresh, K. Attwood, 2021, Blood.

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

A. Zelenetz, M. Geyer, A. Wiestner, 2020, Blood.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

J. Byrd, T. Kipps, M. Dwyer, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Michael L. Wang, A. Alencar, I. Flinn, 2021, The Lancet.

Bone Marrow Structure and Marrow Aspiration, Biopsy, and Collection for Therapeutic Intent Procedures

H. Lazarus, H. Meyerson, S. Sundaram, 2018, Concise Guide to Hematology.

Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.

Scott E. Smith, I. Lossos, P. Venugopal, 2020, Blood.

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Clinical Lymphoma Myeloma and Leukemia.

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

I. Lossos, P. Venugopal, A. Evens, 2021, Haematologica.

Burkitt Lymphoma International Prognostic Index.

Scott E. Smith, I. Lossos, S. Montoto, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma

F. Hernandez-Ilizaliturri, C. Mavis, P. Torka, 2020, EJHaem.

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

A. Evens, F. Hernandez-Ilizaliturri, J. Goldberg, 2021, Blood.

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Sonali M. Smith, P. Venugopal, S. Singer, 2023, Leukemia & lymphoma.

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.

R. Advani, J. Vose, Luu Q. Pham, 2020, Blood advances.

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

F. Hernandez-Ilizaliturri, C. Mavis, P. Torka, 2020, Cancer & Metabolism.

Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models

P. Fu, H. Lazarus, M. Gallogly, 2020, American journal of hematology.

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

F. Hernandez-Ilizaliturri, C. Mavis, P. Torka, 2022, Blood advances.

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Sonali M. Smith, P. Venugopal, S. Singer, 2023, American journal of hematology.

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

F. Hernandez-Ilizaliturri, C. Mavis, P. Torka, 2020, Cancer & Metabolism.

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

I. Lossos, P. Venugopal, A. Evens, 2019, Blood.

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Scott E. Smith, I. Lossos, P. Venugopal, 2019, Blood.

Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia

P. Torka, S. Sundaram, E. Conroy, 2020, Annals of Hematology.

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

J. Vose, K. Naresh, Shaoying Li, 2023, Blood advances.